Disclosure under regulation 30 for following items: 1. Re-appointment of Mr. Amit Kumar as Manager(KMP) of the company. 2. Adoption of new set of Memorandum of Association of the Company ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Brawn Biotech Ltd has informed shareholders that at its meeting held on September 30, 2025, two key resolutions were approved. First, Mr. Amit Kumar has been re-appointed as Manager (Key Managerial Personnel) for another 5-year term starting February 12, 2026, running until February 11, 2031. Mr. Amit Kumar, who has over 10 years of experience in pharma operations and sales, will continue in his existing role as the Manager of the company. Second, shareholders approved the adoption of a new Memorandum of Association (MoA) to align it with the current Companies Act, 2013. The company clarifies that there is no change in its main objects — the revision is purely a regulatory housekeeping exercise to update old references from the Companies Act, 1956.
This is a routine administrative and governance update. The re-appointment ensures continuity in leadership with no management disruption, and the MoA revision is a cosmetic compliance step with no change in business focus, so it is unlikely to materially affect the stock price or shareholder interests.